Back
Return
Biography
Prof. Galila Agam

Prof. Galila Agam

Ben Gurion University, Israel

 

Email: galila@bgu.ac.il

 

Qualifications

1984 Ph.D., Ben Gurion University, Beersheva, Israel

1970 M.Sc., Hebrew University and Hebrew University Medical School, Jerusalem

1968 B.Sc., Hebrew University, Jerusalem, Israel

 

Publications (Selected)

  1. Mariotti V, Erika Melissari E, Amar S, Conte A, Belmaker RH, Agam G, Silvia Pellegrini S (2010): Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays. Expt Biol Med, Expt Biol Med  235:300-10. Selected by the journal as a feature article of the month.
  2. Slonimsky A, Levy I, Rigbi A, Kohn Y, Ben-Asher E, Lancet D, Agam G, Lerer B (2010). Lymphoblast and brain expression of AHI1 and the novel primate specific gene, C6orf217, in schizophrenia and bipolar disorder. Schizophrenia Res. 120:159-66.
  3. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, Agam G, Belmaker RH (2010). Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord 12:376-82.
  4. Amar S, Ovadia O, Maier W, Ebstein R, Belmaker RH, Mishmar D, Agam G. (2010). Copy number variation of the SELENBP1 gene in schizophrenia. Behav Brain Funct 6:40.
  5. Dresner E, Agam G, Gozes I. (2010). Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. Eur Neuropsychopharmacol. In Press.
  6. Karyo R, Eskira Y, Pinhasov A, Belmaker R, Agam G, Eldar-Finkelman H (2010). Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci. 45(4):449-55.
  7. Agam G, Bersudsky Y, Belmaker RH. Abnormalities of inositol metabolism in lymphocytes as biomarkers for bipolar disorder In: Neuropsychiatric Biomarkers, Endophenotypes and Genes: Promises, Advances and Challenges. Ritsner MS (ed.), Springer, 2009.
  8. Mann L, Shaltiel G, Belmaker RH, Heldman E, Agam G, 2008. Lithium perferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol. 11:533-9.
  9. Bersudsky Y, Shaldubina A, Agam G, Berry GT, Belmaker RH (2008): Homozygote inositol transporter knockout mice show a lithium-like phenotype. Bipolar Disord: 10:453459.
  10. Belmaker RH, Agam G, Bersudsky Y. Role of GSK3beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A. 2008 May 20;105(20):E23; author reply E24. Epub 2008 May 12.
  11. Belmaker RH, Agam G, 2008. Major Depressive Disorder. New Engl J Med, Mechanisms of Disease 358:47-60. An invited review.
  12. Cryns K, Shamir A, Levi I, Daneels G, Goris I, Delille P, Bouwknecht A,  Kass S, Agam G, Belmaker RH, Bersudsky Y, Steckler T, Moechars D, 2008. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychophopharmacology 33:674-84.
  13. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, Bersudsky Y, Belmaker RH, Agam G, 2008: Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 11:197-205.
  14. Belmaker RH, Agam G, Lenox RH (2008): Neurobiology and pharmacotherapy of bipolar disorder In: Handbook of Contemporary Neuropharmacology. Sibley D, Hanin I, Kuhar M, Skolnick P (eds.) Vol. 1, Part II: Mood Disorders. Chapter 22, pp. 859-876, 2007, APP Press.
  15. Cryns K, Shamir A, Shapiro F, Daneels G, Goris I, Hansfried Van Craenendonck H, Straetemans R, Belmaker RH, Agam G, Moechars D, Steckler T, 2007. Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 32:881-891.
  16. Shaldubina A, Buccafusca R, Johanson R, Agam G, Belmaker RH, Berry G, Bersudsky Y, 2007. Behavioral Phenotyping of sodium-myo-inositol cotransporter knockout Mice with reduced brain Inositol, Genes Brain Behav 6:253-259.
  17. Shaltiel G, Dalton CE, Belmaker RH, Harwood JA, Agam G, 2007. Specificity of Mood Stabilizer Action on Neuronal Growth Cones, Bipolar Disorders 9:281-289.
  18. Bendikov I, Nadri C, Amar S, Panizzutti RA, De Miranda J, Wolosker H, Agam G, 2007. D-Serine Metabolic Parameters in Schizophrenia; A CSF and Postmortem Brain Study. Schizophrenia Res. 90:41-51.
  19. Shamir A, Shaltiel G, Mark S, Bersudsky Y, Belmaker RH and Agam G, 2007. Human MIP synthase splice variants in bipolar disorder. Bipolar Disorders 9:766-771.
  20. Amar S, Shamir A, Ovadia O, Blanaru M, Reshef A, Kremer I, Rietschel M,  Schulze TG,  Maier W, Belmaker RH, Ebstein RP, Agam G,  Mishmar D, 2007. Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. Schizophrenia Res 94: 354-358.
  21. Kozlovsky N, Amar S, Belmaker RH, Agam G, 2006. Psychotropic drugs affect Ser-9-phosphorylated protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol. bGSK3 9:337-42.
  22. Shaltiel G, Shamir A, Levy I, Bersudsky Y, Agam G, 2006. Lymphocyte G-protein receptor kinase (GRK)3 mRNA levels in bipolar disorder. Int J Neuropsychpharmacol, 9:761-766.
  23. Shaltiel G, Shamir A, Agam G, Belmaker R.H: Only tryptophan hydroxylase (TPH)-2 is relevant to the CNS. Am J Med Genetics B Neuropsychiatr Genet. (letter to the editor) 136:106, 2005.
  24. Belmaker RH, Agam G: Bipolar Disorder: neurochemistry and drug mechanisms. Discovery Medicine 5:191-198, 2005.